



hmz73 &lt;hamzah\_hasyim@fkm.unsri.ac.id&gt;

---

**[ABM] Editor Decision: Revisions Required**

1 pesan

**Prof. Maurizio Vanelli** <noreply@mattioli1885journals.com>

21 September 2021 22.33

Kepada: Ahmad Ghiffari <dokter.ghi@gmail.com>, Chairil Anwar <chairil53@fk.unsri.ac.id>, Indri Ramayanti <indrifkump@gmail.com>, Hamzah Hasyim <hamzah\_hasyim@fkm.unsri.ac.id>, Iskhaq Iskandar <iskhaq.iskandar@gmail.com>, Muhammad Totong Kamaluddin <mtk52@yahoo.com>, Legiran Legiran <legiran@yahoo.com>, Zulkhair Ali <riset.drzulkhair@gmail.com>

Ahmad Ghiffari, Chairil Anwar, Indri Ramayanti, Hamzah Hasyim, Iskhaq Iskandar, Muhammad Totong Kamaluddin, Legiran Legiran, Zulkhair Ali:

We have reached a decision regarding your submission to Acta Biomedica Atenei Parmensis, "SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in COVID-19 Pandemic Palembang Indonesia: SARS-CoV-2 Variants of Concern in Palembang Indonesia".

Submission URL: <https://mattioli1885journals.com/index.php/actabiomedica/authorDashboard/submission/12224>

Our decision is: Revisions Required . Authors are invited to carefully consider the referees remarks, in particular the English version. We remind you that all linguistic changes and updates must be reported in red in the manuscript

**When revising your manuscript, please show corrections by using track changes or highlighting them in red color. Be sure to respond to all reviewer comments including also a letter with your comments about. You should upload two files: 1) Revised manuscript file with changes highlighted or in red colour. 2) File containing response to reviewers.**

Thanks for your collaboration

Kind regards,

**[THIS IS AN AUTOMATED MESSAGE - PLEASE DO NOT REPLY DIRECTLY TO THIS EMAIL]**

Professor Maurizio Vanelli, MD Editor-in-chief, Acta Biomedica, University of Parma Phone +39 0521 033556 Mobile: +39 335 348878 [maurizio.vanelli@unipr.it](mailto:maurizio.vanelli@unipr.it)

-----  
Reviewer A:

Estimated Authors,

Estimated Editors of ABM,

I've read with significant interest the present article entitled "SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in COVID-19 Pandemic Palembang Indonesia". Authors have reported about their genetic surveillance on the VOC / VOI in Indonesia, ultimately providing some significant glimpses on the current epidemiology of this pathogen. Furthermore, the analyses suggest some interesting heterogeneities in the epidemiology of the various VOC, as well as regarding the sensitivity to the vaccines employed for the mass vaccination campaign.

The present paper is, therefore, both interesting and consistent with the aims of ABM. Moreover, its overall quality is appropriate for an international biomedical journal despite its content may appear of somewhat limited scope (i.e. it reports only on Indonesian epidemiology of SARS-CoV-2).

However, I think that some significant improvements are required before its final acceptance, mostly regarding the English Editing.

In fact, the paper seems somehow dichotomized, with an introduction and methods section that are of good quality in terms of English text, with a Results/Discussion section affected by jargon and typos (e.g. "The accumulative number of COVID-19 transmissions " instead of "The cumulative..."; look at the following section: "*Alpha variant with the E484K mutation may be more successful at reinfection. The E484K means amino acid changes at the specified position of 484 mutation E to K, and the E484K mutation is considered the escape mutation. The E484K mutation, among other things, can weaken the immune response and decrease the duration of the neutralizing antibody response. The E484K mutation has been found in several variants, including the Beta and Gamma (30).*" even though it is grammatically correct, the text would profit from an extensive but basic English editing, etc.)

In summary, please provide an editing of the English text - particularly for the latter sections. After such improvements, the paper may be accepted for publication.

Reading your work and re-assessing it after the requested editing was and would a pleasure.

Recommendation: Revisions Required

-----

*Acta Biomedica Atenei Parmensis*  
Editorial Office  
E-mail: [valeriaceci@mattiolihealth.com](mailto:valeriaceci@mattiolihealth.com)  
<http://www.actabiomedica.it>



hmz73 &lt;hamzah\_hasyim@fkm.unsri.ac.id&gt;

---

**[ABM] Editor Decision: Accept Submission**

1 pesan

**Prof. Maurizio Vanelli** <noreply@mattioli1885journals.com>

1 Oktober 2021 01.06

Kepada: Ahmad Ghiffari <dokter.ghi@gmail.com>, Chairil Anwar <chairil53@fk.unsri.ac.id>, Indri Ramayanti <indrifkump@gmail.com>, Hamzah Hasyim <hamzah\_hasyim@fkm.unsri.ac.id>, Iskhaq Iskandar <iskhaq.iskandar@gmail.com>, Muhammad Totong Kamaluddin <mtk52@yahoo.com>, Legiran Legiran <legiran@yahoo.com>, Zulkhair Ali <riset.drzulkhair@gmail.com>

Dear Ahmad Ghiffari, Chairil Anwar, Indri Ramayanti, Hamzah Hasyim, Iskhaq Iskandar, Muhammad Totong Kamaluddin, Legiran Legiran, Zulkhair Ali:

I am pleased to inform you that your paper to Acta Biomedica Atenei Parmensis, "SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in COVID-19 Pandemic Palembang Indonesia: SARS-CoV-2 Variants of Concern in Palembang Indonesia" has received positive comments from both the referees and the editorial board and therefore **has been accepted for publication in ABM.**

**It will be published in one of the next issues (n 1/22)** . We will send you the galley proofs for corrections as soon as available and before the publication of the article

I thank you for this important contribution and I hope to receive further papers from your Group.

Sincerely

Maurizio Vanelli  
Editor in chief

Submission URL: <https://mattioli1885journals.com/index.php/actabiomedica/authorDashboard/submission/12224>

**Publisher's note - Please pay attention to these instructions:**

We remember to Authors that the Journal has changed its policy and the publication fee has been added. The **fee for the articles submitted starting from the 1st January 2021** should be paid after the acceptance of the article and before the publication. The corresponding authors are responsible for making the payment or arranging it through their institutions. **Only after receiving the payment we will proceed with the publication in the next available issue.** We have a lot of accepted articles and now the next available issue is the vol. 1/2022 (February 2022 issue). (Letters to the Editor as well as reviews, editorial papers, and all articles requested by the Editor in Chief and Section Editors will be published free of charge).

**The fee (366 euro - VAT included) can be paid by paypal/credit card at [Publication Fee form-Acta Biomedica](#)**

(For other payment method please see [here](#))

As soon as we receive the payment we will send you the number of the issue in which your article will be published and the DOI number of the article. We will also activate the plugin "Online first" and so you will be able to see your articles already online before the publication at the end of the website homepage in the "Online first" section.

For info: <https://www.mattioli1885journals.com/index.php/actabiomedica/publicationfee>

With many thanks for your cooperation and kind regards,

*Editorial Office Acta Biomedica*

**[THIS IS AN AUTOMATED MESSAGE - PLEASE DO NOT REPLY DIRECTLY TO THIS EMAIL]**

Professor Maurizio Vanelli, MD Editor-in-chief, Acta Biomedica, University of Parma Phone +39 0521 033556 Mobile: +39 335 348878 [maurizio.vanelli@unipr.it](mailto:maurizio.vanelli@unipr.it)

*Acta Biomedica Atenei Parmensis*

Editorial Office

E-mail: [valeriaceci@mattiolihealth.com](mailto:valeriaceci@mattiolihealth.com)

<http://www.actabiomedica.it>